Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)

$CRDL Has Completed a $16 Million Private Placement and Closed a Financing for Gross Proceeds of $14.85 Million, Providing Cash Into Q4 2027 Late-Stage Life…
posteditor
posteditor
Articles: 17424

Other News